Sotera Health (NASDAQ:SHC) Price Target Lowered to $16.00 at Barclays

Sotera Health (NASDAQ:SHC) had its price objective trimmed by Barclays from $17.00 to $16.00 in a research report released on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

SHC has been the subject of a number of other research reports. The Goldman Sachs Group initiated coverage on shares of Sotera Health in a research note on Friday, December 6th. They set a “neutral” rating and a $14.00 target price for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a research note on Thursday, November 21st. Finally, Citigroup upped their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Sotera Health currently has an average rating of “Moderate Buy” and a consensus price target of $15.92.

Sotera Health Trading Up 1.5 %

Shares of Sotera Health stock opened at $12.47 on Friday. The firm has a 50-day simple moving average of $13.45 and a two-hundred day simple moving average of $14.51. The company has a market cap of $3.53 billion, a P/E ratio of 49.88 and a beta of 1.91. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.08. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88.

Institutional Trading of Sotera Health

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in shares of Sotera Health by 19.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock valued at $46,026,000 after buying an additional 447,186 shares during the period. Maven Securities LTD purchased a new stake in shares of Sotera Health in the 3rd quarter valued at approximately $1,670,000. Cerity Partners LLC purchased a new stake in shares of Sotera Health in the 3rd quarter valued at approximately $1,489,000. Neo Ivy Capital Management purchased a new stake in shares of Sotera Health in the 3rd quarter valued at approximately $720,000. Finally, Barclays PLC lifted its holdings in shares of Sotera Health by 169.8% in the 3rd quarter. Barclays PLC now owns 473,597 shares of the company’s stock worth $7,909,000 after acquiring an additional 298,085 shares during the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.